This article is more than 5 years old. Information may no longer be current.

VIDEO: Intensity Therapeutics’ intratumoral formulation active in highly refractory cancers

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Lewis H. Bender, MS, MA, MBA, founder, president and CEO of Intensity Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about preliminary results of the company’s ongoing phase 1/phase 2 trial of its lead product candidate.

INT230-6, a novel intratumoral formulation, consists of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine.

To date, more than 34 patients with highly refractory cancers — including triple-negative breast cancer and sarcoma — have been treated.

A poster presented at ASCO showed the drug reduced tumors into which it was injected, and researchers also reported reductions of untreated lesions in some patients.

“We are seeing very exciting tumor regression in very difficult-to-treat patients,” Bender told HemOnc Today.

In the next 12 months, company officials expect to begin a study of INT230-6 in combination with immune checkpoint inhibitors.

“We have shown in nonclinical studies that our drug synergizes extremely well,” Bender said. – by Mark Leiser

Reference: El-Khoueiry AB, et al. Abstract 2602. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.